DTI and MR Volumetry of Hippocampus-PC/PCC Circuit: In Search of Early Micro- and Macrostructural Signs of Alzheimers's Disease by F. Palesi, P. Vitali, P. Chiarati, G. Castellazzi, E. Caverzasi, A. Pichiecchio, E. Colli-Tibaldi, F. D'Amore, I. D'Errico, E. Sinforiani, S. Bastianello

“…Hippocampal damage, by DTI or MR volumetry, and PET hypoperfusion of precuneus/posterior cingulate cortex (PC/PCC) were proposed as biomarkers of conversion from preclinical (MCI) to clinical stage of Alzheimer's disease (AD). …”
Get full text

Effectiveness of Contrast Agents and Molecular Indicators in Alzheimer's Diagnosis Through PET and SPECT Imaging on Animal Models by Yasaman Abaszadeh, Ramin Ardalani, Athena Dehghan Najm Abadi

Get full text

Cognitive Phenotypes, Brain Morphometry and the Detection of Cognitive Decline in Preclinical AD by Mark W. Jacobson, Linda K. McEvoy, Anders Dale, Christine Fennema-Notestine

“…Identifying a preclinical phase of Alzheimer’s Disease (PCAD) that is distinct from cognitive changes in healthy aging continues to be a major research focus. …”
Get full text

APOE4 and infectious diseases jointly contribute to brain glucose hypometabolism, a biomarker of Alzheimer's pathology: New findings from the ADNI. by Aravind Lathika Rajendrakumar, Konstantin G Arbeev, Olivia Bagley, Matt Duan, Anatoliy I Yashin, Svetlana Ukraintseva, Alzheimer’s Disease Neuroimaging Initiative

“…<h4>Background</h4>Impaired brain glucose metabolism is a preclinical feature of neurodegenerative diseases such as Alzheimer's disease (AD). …”
Get full text

Machine learning models for dementia screening to classify brain amyloid positivity on positron emission tomography using blood markers and demographic characteristics: a retrospec... by Noriyuki Kimura, Kotaro Sasaki, Teruaki Masuda, Takuya Ataka, Mariko Matsumoto, Mika Kitamura, Yosuke Nakamura, Etsuro Matsubara

“…Abstract Background Intracerebral amyloid β (Aβ) accumulation is considered the initial observable event in the pathological process of Alzheimer’s disease (AD). Efficient screening for amyloid pathology is critical for identifying patients for early treatment. …”
Get full text

Quantification and correlation of amyloid-β plaque load, glial activation, GABAergic interneuron numbers, and cognitive decline in the young TgF344-AD rat model of Alzheimer’s dise... by Anett Futácsi, Anett Futácsi, Anett Futácsi, Kitti Rusznák, Kitti Rusznák, Gergely Szarka, Gergely Szarka, Gergely Szarka, Béla Völgyi, Béla Völgyi, Ove Wiborg, Boldizsár Czéh, Boldizsár Czéh, Boldizsár Czéh

“…BackgroundAnimal models of Alzheimer’s disease (AD) are essential tools for investigating disease pathophysiology and conducting preclinical drug testing. …”
Get full text

Preclinical use of a clinically-relevant scAAV9/SUMF1 vector for the treatment of multiple sulfatase deficiency by Maximiliano Presa, Rachel M. Bailey, Somdatta Ray, Lauren Bailey, Saurabh Tata, Tara Murphy, Pierre-Alexandre Piec, Harold Combs, Steven J. Gray, Cathleen Lutz

Get full text

Weight trajectories in aging humanized APOE mice with translational validity to human Alzheimer's risk population: A retrospective analysis. by Francesca Vitali, Jean-Paul Wiegand, Lillian Parker-Halstead, Allan Tucker, Roberta Diaz Brinton

“…Translational validity of mouse models of Alzheimer's disease (AD) is variable. Because change in weight is a well-documented precursor of AD, we investigated whether diversity of human AD risk weight phenotypes was evident in a longitudinally characterized cohort of 1,196 female and male humanized APOE (hAPOE) mice, monitored up to 28 months of age which is equivalent to 81 human years. …”
Get full text

Protective effects of wogonin in the treatment of central nervous system and degenerative diseases by Qingan Fu, Qingyun Yu, Hongdan Luo, Zhekang Liu, Xiaowei Ma, Huijian Wang, Zhijuan Cheng

“…Moreover, wogonin shows promise in treating neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease by promoting autophagy and reducing neuroinflammation. …”
Get full text

Virtual Screening, Toxicity Evaluation and Pharmacokinetics of Erythrina Alkaloids as Acetylcholinesterase Inhibitor Candidates from Natural Products by Permana A, Akili AWR, Hardianto A, Latip JB, Sulaeman AP, Herlina T

“…These results warrant further investigation in preclinical and clinical studies to validate its therapeutic potential and safety for Alzheimer’s disease treatment.Keywords: Erythrina alkaloid, pharmacokinetics, In silico, acetylcholinesterase inhibitors, virtual screening…”
Get full text

EVALUATION OF THE THERAPEUTIC EFFECTS OF SALVIA ROSMARINUS ESSENTIAL OIL ON NERVOUS SYSTEM DISORDERS by Malina Mihaela Visternicu, Viorica Rarinca, Vasile Burlui, Alin Ciobica

“…This review explores the therapeutic potential of rosemary in alleviating nervous system disorders such as Alzheimer's disease (AD), major depressive disorder (MDD), epilepsy, Parkinson's disease (PD), addiction, and attention-deficit hyperactivity disorder (ADHD). …”
Get full text

The protective role of GLP-1 in neuro-ophthalmology by Sohum Sheth, Aashay Patel, Marco Foreman, Mohammed Mumtaz, Akshay Reddy, Ramy Sharaf, Siddharth Sheth, Brandon Lucke-Wold

“…This article identifies the sources and targets of GLP-1 in the brain and review the mechanisms which mediate its neuroprotective effects, as well as implications for Alzheimer’s disease (AD) and Parkinson’s disease (PD). …”
Get full text

Implications of the Intestinal Microbiota in Diagnosing the Progression of Diabetes and the Presence of Cardiovascular Complications by Alina Mihaela Leustean, Manuela Ciocoiu, Anca Sava, Claudia Florida Costea, Mariana Floria, Claudia Cristina Tarniceriu, Daniela Maria Tanase

“…Microbes can be considered a complex endocrine system capable of ensuring the proper functioning of the body but are also responsible for the development of numerous pathologies (diabetes, coronary syndromes, peripheral arterial disease, neoplasia, Alzheimer’s disease, and hepatic steatosis). …”
Get full text

Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications by Pharaoh Fellow Mwale, Cheng-Ta Hsieh, Ting-Lin Yen, Jing-Shiun Jan, Rajeev Taliyan, Chih-Hao Yang, Wen-Bin Yang

“…It has emerged as a significant player in various neurodegenerative diseases and brain disorders. Elevated CHI3L1 levels have been observed in neurological conditions such as traumatic brain injury (TBI), Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic lateral sclerosis (ALS), Creutzfeldt-Jakob disease (CJD), multiple sclerosis (MS), Neuromyelitis optica (NMO), HIV-associated dementia (HAD), Cerebral ischemic stroke (CIS), and brain tumors. …”
Get full text

Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences by Gloria Ortiz-Guerrero, Diana Amador-Muñoz, Carlos Alberto Calderón-Ospina, Daniel López-Fuentes, Mauricio Orlando Nava Mesa

“…Alzheimer’s disease (AD) is the most common type of dementia, mainly encompassing cognitive decline in subjects aged ≥65 years. …”
Get full text

Molecular Mechanisms of Neurodegeneration Related to C9orf72 Hexanucleotide Repeat Expansion by Mirjana Babić Leko, Vera Župunski, Jason Kirincich, Dinko Smilović, Tibor Hortobágyi, Patrick R. Hof, Goran Šimić

Get full text